

### AMENDMENTS TO THE CLAIMS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims:**

Claim 1 (Currently Amended): A method of treating multiple sclerosis (MS), ~~including the step of~~ comprising administering to an individual ~~[[a]]~~ pharmaceutically-effective amount amounts of cpn10 and IFN- $\beta$  wherein the therapeutic effect of administering cpn10 and IFN- $\beta$  is greater than that of administering an equivalent amount of cpn10 or IFN- $\beta$  alone.

Claim 2 (Original): The method of claim 1, when used as a treatment to prevent relapse of MS.

Claim 3 (Previously Presented): The method of claim 1, wherein IFN- $\beta$  and cpn10 are administered together.

Claim 4 (Previously Presented): The method of claim 1, wherein IFN- $\beta$  and cpn10 are administered separately.

Claim 5 (Original): The method of claim 3, wherein IFN- $\beta$  and cpn10 are administered by injection.

Claim 6 (Original): The method of claim 4, wherein cpn10 is administered orally.

Claim 7 (Previously Presented): The method of claim 4, wherein IFN- $\beta$  is administered by injection.

Claim 8 (Currently Amended): The ~~process~~ method of claim 1, wherein the pharmaceutically effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10.

Claim 9 (Original): The method of claim 8, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

Claim 10 (Original): The method of claim 1, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 Million International Units (MIU) of IFN- $\beta$ .

Claim 11 (Currently Amended): The method of claim 10, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 ~~(MIU)~~ MIU of IFN- $\beta$ .

Claim 12 (Withdrawn): A pharmaceutical composition for treating MS, wherein said composition an amount of cpn10 and of IFN- $\beta$  effective to treat MS in combination with a pharmaceutically-acceptable carrier or diluent.

Claim 13 (Withdrawn): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10.

Claim 14 (Withdrawn): The composition of claim 13, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

Claim 15 (Withdrawn): The composition of claim 12, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 MIU of IFN- $\beta$ .

Claim 16 (Withdrawn): The composition of claim 15, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 MIU of IFN- $\beta$ .

Claim 17 (Withdrawn): A kit comprising an amount of cpn10 and IFN- $\beta$  effective to treat MS and, in a separate container, a pharmaceutically-acceptable carrier or diluent.

Claim 18 (Withdrawn): The kit of claim 17, wherein said IFN- $\beta$  is in dehydrated form, which in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

Claim 19 (Withdrawn): The kit of claim 18, wherein said cpn10 is in dehydrated form and in use, is rehydrated by said pharmaceutically-acceptable carrier or diluent.

Claim 20 ((Withdrawn): The kit of claim 17, wherein said cpn10 is in tablet or capsule form.

Claim 21 (Withdrawn): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 5-60 mg of cpn10.

Claim 22 (Withdrawn): The kit of claim 21, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 10-30 mg of cpn10.

Claim 23 (Withdrawn): The kit of claim 17, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 1-10 MIU of IFN- $\beta$ .

Claim 24 (Withdrawn): The kit of claim 23, wherein the pharmaceutically-effective amount of cpn10 and IFN- $\beta$  comprises 4-6 MIU of IFN- $\beta$ .